Victory Capital Management Inc. Buys 21,135 Shares of Moderna, Inc. (NASDAQ:MRNA)

Victory Capital Management Inc. lifted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 7.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 303,132 shares of the company’s stock after acquiring an additional 21,135 shares during the quarter. Victory Capital Management Inc.’s holdings in Moderna were worth $30,146,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Allworth Financial LP grew its position in shares of Moderna by 6.5% during the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after buying an additional 101 shares during the period. TIAA Trust National Association grew its holdings in Moderna by 2.3% in the fourth quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock worth $447,000 after purchasing an additional 102 shares during the period. Sound Income Strategies LLC increased its stake in Moderna by 17.8% in the fourth quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock valued at $76,000 after purchasing an additional 115 shares in the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors raised its holdings in shares of Moderna by 6.5% during the fourth quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 2,459 shares of the company’s stock valued at $245,000 after purchasing an additional 151 shares during the period. Finally, Bristlecone Advisors LLC boosted its position in shares of Moderna by 2.6% during the 4th quarter. Bristlecone Advisors LLC now owns 5,999 shares of the company’s stock worth $597,000 after purchasing an additional 153 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Down 0.9 %

Shares of Moderna stock opened at $121.07 on Wednesday. The company has a 50-day simple moving average of $106.10 and a two-hundred day simple moving average of $95.05. The stock has a market capitalization of $46.40 billion, a PE ratio of -7.73 and a beta of 1.57. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $142.79. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. During the same quarter last year, the firm earned $0.19 earnings per share. The firm’s quarterly revenue was down 91.0% compared to the same quarter last year. On average, analysts anticipate that Moderna, Inc. will post -7.47 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 price target on shares of Moderna in a report on Tuesday, April 9th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Thursday, May 2nd. Royal Bank of Canada upped their price objective on shares of Moderna from $125.00 to $135.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Oppenheimer lifted their price objective on shares of Moderna from $142.00 to $163.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Finally, HSBC restated a “reduce” rating and issued a $86.00 target price (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $126.89.

Insider Activity

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total value of $1,663,800.00. Following the transaction, the director now directly owns 2,026,931 shares of the company’s stock, valued at $224,827,186.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total value of $1,663,800.00. Following the transaction, the director now directly owns 2,026,931 shares of the company’s stock, valued at approximately $224,827,186.52. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Shannon Thyme Klinger sold 544 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $99.05, for a total value of $53,883.20. Following the completion of the transaction, the insider now directly owns 9,267 shares in the company, valued at approximately $917,896.35. The disclosure for this sale can be found here. Insiders have sold 139,954 shares of company stock valued at $14,822,576 in the last ninety days. 15.20% of the stock is currently owned by company insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.